Lyell Immunopharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.025 million compared to USD 0.003 million a year ago. Net loss was USD 50.85 million compared to USD 70.25 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.28 a year ago.
For the nine months, sales was USD 0.117 million compared to USD 36.3 million a year ago. Net loss was USD 181.7 million compared to USD 174.72 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 0.71 a year ago.